Trimeris, Inc.

Other

Paul Erickson Friedrich

Brian L Bray

Marc W Andersen

Huyi Zhang

Stephen E Schneider

Myung-Chol Kang

John Dwyer

Barbara E Johnston

Nicolai A Tvermoes

Nikolai A Tvermores

Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.

HIV fusion inhibitor peptides with improved biological properties

The present invention relates, first, to methods for the synthesis of peptides referred to as T-1249 and T-1249-like peptides. Such methods utilize solid and liquid phase synthesis procedures to synthesize and combine groups of specific peptide fragments to yield the peptide of interest. The present invention further relates to individual peptide fragments which act as intermediates in the synthesis of the peptides on interest (e.g., T-1249). The present invention still further relates to groups of such peptide intermediate fragments which can be utilized together to produce full-length T-1249 and T-1249-like peptides.

Methods and compositions for peptide synthesis

Methods and composition for peptide synthesis

Growing community of inventors

Apex, NC, United States of America

Paul Erickson Friedrich